nach oben

International Journal of Clinical Oncology

Erschienen in:

20.01.2020 | Original Article

Postradiotherapy persistent lymphopenia as a poor prognostic factor in patients with cervical cancer receiving radiotherapy: a single-center, retrospective study

verfasst von: Ayumi Taguchi, Akiko Furusawa, Kei Ito, Yujiro Nakajima, Takuya Shimizuguchi, Konan Hara, Maki Takao, Tomoko Kashiyama, Nao Kino, Katsuyuki Karasawa, Toshiharu Yasugi

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Radiotherapy (RT) is effective in cervical cancer; radiation-induced lymphopenia correlates with poor survival outcome in several cancer types. We investigated the association of total lymphocyte count (TLC) with survival outcomes in patients with cervical cancer.

Methods

We retrospectively reviewed 168 patients with cervical cancer initially treated with definitive RT. We obtained clinicopathological data and TLCs before RT and at the end and at 6 months after RT. Patient-, treatment-, and tumor-specific factors were evaluated to determine their predictive values for overall survival. The association of overall and progression-free survivals with lymphopenia at each point was evaluated.

Results

Median follow-up duration was 44 (interquartile range: 25–67) months. Median TLCs before RT and at the end and at 6 months after RT were 1625/mm³, 400/mm³, and 800/mm³ (interquartile range: 1270–1930/mm³, 290–550/mm³, and 600–1067/mm³), respectively. For overall survival, in addition to FIGO stage, body mass index, histology, treatment, and presence of para-aortic lymph node metastasis, lymphopenia at 6 months after RT was a poor prognostic factor in multivariate analysis (P = 0.0026; hazard ratio [HR], 3.06; 95% confidence interval [CI]: 1.48–6.33). For progression-free survival, TLCs before and at 6 months after RT were poor prognostic factors in univariate analysis (P = 0.0318 and 0.0081, respectively); however, the latter was the only independent prognostic factor in multivariate analysis (P = 0.0021; HR, 2.67; 95% CI: 1.43–4.99).

Conclusion

Post-RT persistent lymphopenia could be a poor prognostic factor for patients with cervical cancer who receive RT.

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30. https://doi.org/10.3322/caac.21442 CrossRefPubMed

Rose PG, Bundy BN, Watkins EB et al (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144–1153CrossRefPubMed

Morris M, Eifel PJ, Lu J et al (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137–1143CrossRefPubMed

National Cancer Center National database of hospital-based cancer registries: 5 year survival report 2008–2009. National Cancer Center, Tokyo. https://ganjoho.jp/data/reg_stat/statistics/brochure/hosp_c_reg_surv_all_2008-2009.pdf. Accessed Feb 2019

Formenti SC, Demaria S (2013) Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105:256–265. https://doi.org/10.1093/jnci/djs629 CrossRefPubMedPubMedCentral

Tsukumo SI, Yasutomo K (2018) Regulation of CD8⁺ T cells and antitumor immunity by Notch signaling. Front Immunol 9:101. https://doi.org/10.3389/fimmu.2018.00101eCollection CrossRefPubMedPubMedCentral

Kuss I, Hathaway B, Ferris RL et al (2004) Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10:3755–3762CrossRefPubMed

Grossman SA, Ye X, Lesser G et al (2011) NABTT CNS consortium. immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res 17:5473–5480. https://doi.org/10.1158/1078-0432.CCR-11-0774 CrossRefPubMedPubMedCentral

Mendez JS, Govindan A, Leong J et al (2016) Association between treatment-related lymphopenia and overall survival in elderly patients with newly diagnosed glioblastoma. J Neurooncol 127:329–335. https://doi.org/10.1007/s11060-015-2037-1 CrossRefPubMedPubMedCentral

10.

Tang C, Liao Z, Gomez D et al (2014) Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys 89:1084–1091. https://doi.org/10.1016/j.ijrobp.2014.04.025 CrossRefPubMed

11.

Cho O, Oh YT, Chun M et al (2016) Radiation-related lymphopenia as a new prognostic factor in limited-stage small cell lung cancer. Tumour Biol 37:971–978. https://doi.org/10.1007/s13277-015-3888-y CrossRefPubMed

12.

Fang P, Jiang W, Davuluri R et al (2018) High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer. Radiother Oncol 128:584–590. https://doi.org/10.1016/j.radonc.2018.02.025 CrossRefPubMed

13.

Campian JL, Sarai G, Ye X et al (2014) Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck 36:1747–1753. https://doi.org/10.1002/hed.23535 CrossRefPubMedPubMedCentral

14.

Kuo P, Bratman SV, Shultz DB et al (2014) Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response. Clin Cancer Res 20:5558–5569. https://doi.org/10.1158/1078-0432.CCR-14-1138 CrossRefPubMedPubMedCentral

15.

Wild AT, Ye X, Ellsworth SG et al (2015) The association between chemoradiation-related lymphopenia and clinical outcomes in patients with locally advanced pancreatic adenocarcinoma. Am J Clin Oncol 38:259–265. https://doi.org/10.1097/COC.0b013e3182940ff9 CrossRefPubMedPubMedCentral

16.

Venkatesulu BP, Mallick S, Lin SH et al (2018) A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol 123:42–51. https://doi.org/10.1016/j.critrevonc.2018.01.003 CrossRefPubMed

17.

Wu ES, Oduyebo T, Cobb LP et al (2016) Lymphopenia and its association with survival in patients with locally advanced cervical cancer. Gynecol Oncol 140:76–82. https://doi.org/10.1016/j.ygyno.2015.11.013 CrossRefPubMed

18.

Cho O, Chun M, Oh YT et al (2017) Prognostic implication of simultaneous anemia and lymphopenia during concurrent chemoradiotherapy in cervical squamous cell carcinoma. Tumour Biol 39:1010428317733144. https://doi.org/10.1177/1010428317734303 CrossRefPubMed

19.

Cho O, Chun M, Chang SJ et al (2016) Prognostic value of severe lymphopenia during pelvic concurrent chemoradiotherapy in cervical cancer. Anticancer Res 36:3541–3547PubMed

20.

Yoshino Y, Taguchi A, Takao M et al (2019) Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer. Int J Clin Oncol 24:4280436. https://doi.org/10.1007/s10147-018-1374-4 CrossRef

21.

Ray-Coquard I, Cropet C, Van Glabbeke M et al (2009) European organization for research and treatment of cancer soft tissue and bone sarcoma group. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69:5383–5391. https://doi.org/10.1158/0008-5472.CAN-08-3845 CrossRefPubMedPubMedCentral

22.

Cézé N, Thibault G, Goujon G et al (2011) Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol 68:1305–1313. https://doi.org/10.1007/s00280-011-1610-3 CrossRefPubMed

23.

Kobayashi N, Usui S, Kikuchi S et al (2012) Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer. Lung Cancer 75:223–227. https://doi.org/10.1016/j.lungcan.2011.06.009 CrossRefPubMed

24.

Feng JF, Liu JS, Huang Y (2014) Lymphopenia predicts poor prognosis in patients with esophageal squamous cell carcinoma. Medicine (Baltimore) 93:e257. https://doi.org/10.1097/MD.0000000000000257 CrossRef

25.

Kou F, Lu Z, Li J et al (2016) Pretreatment lymphopenia is an easily detectable predictive and prognostic marker in patients with metastatic esophagus squamous cell carcinoma receiving first-line chemotherapy. Cancer Med 5:778–786. https://doi.org/10.1002/cam4.638 CrossRefPubMedPubMedCentral

26.

Joseph N, Dovedi SJ, Thompson C et al (2016) Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer. Ann Oncol 27:294–299. https://doi.org/10.1093/annonc/mdv546 CrossRefPubMed

27.

Dahmani A, Delisle JS (2018) TGF-β in T cell biology: implications for cancer immunotherapy. Cancers (Basel). https://doi.org/10.3390/cancers10060194 CrossRef

28.

Gorelik L, Flavell RA (2002) Transforming growth factor-beta in T-cell biology. Nat Rev Immunol 2:46–53CrossRefPubMed

29.

Tsukamoto H, Fujieda K, Senju S et al (2018) Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity. Cancer Sci 109:523–530. https://doi.org/10.1111/cas.13433 CrossRefPubMed

30.

Nakamura N, Kusunoki Y, Akiyama M (1990) Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. Radiat Res 123:224–227CrossRefPubMed

31.

Yovino S, Kleinberg L, Grossman SA et al (2013) The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest 31:140–144. https://doi.org/10.3109/07357907.2012.762780 CrossRefPubMedPubMedCentral

32.

Raben M, Walach N, Galili U et al (1976) The effect of radiation therapy on lymphocyte subpopulations in cancer patients. Cancer 37:1417–1421CrossRefPubMed

33.

Sini C, Fiorino C, Perna L et al (2016) Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation. Radiother Oncol 118:79–84. https://doi.org/10.1016/j.radonc.2015.11.020 CrossRefPubMed

Titel: Postradiotherapy persistent lymphopenia as a poor prognostic factor in patients with cervical cancer receiving radiotherapy: a single-center, retrospective study
verfasst von: Ayumi Taguchi
Akiko Furusawa
Kei Ito
Yujiro Nakajima
Takuya Shimizuguchi
Konan Hara
Maki Takao
Tomoko Kashiyama
Nao Kino
Katsuyuki Karasawa
Toshiharu Yasugi
Publikationsdatum: 20.01.2020
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 5/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-020-01623-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Postradiotherapy persistent lymphopenia as a poor prognostic factor in patients with cervical cancer receiving radiotherapy: a single-center, retrospective study

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101-

Current issues and perspectives in PD-1 blockade cancer immunotherapy

Operation for locally advanced cervical cancer after concurrent chemoradiotherapy

Magnitude of advantage in tumor response contributes to a better correlation between treatment effects on overall survival and progression-free survival: a literature-based meta-analysis of clinical trials in patients with metastatic colorectal cancer

Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis

Treatment choices and outcomes of non-metastatic hepatocellular carcinoma patients in relationship to neighborhood socioeconomic status: a population-based study

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie